We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-17.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$977M
AUM Growth
-$359M
Cap. Flow
-$135M
Cap. Flow %
-13.86%
Top 10 Hldgs %
55.77%
Holding
68
New
11
Increased
16
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.9M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$27.6M
3
BKD icon
Brookdale Senior Living
BKD
+$21.8M
4
AET
Aetna Inc
AET
+$20.5M
5
MOH icon
Molina Healthcare
MOH
+$19.5M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$61.6M
2
WCG
Wellcare Health Plans, Inc.
WCG
+$44M
3
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$38.2M
4
INSM icon
Insmed
INSM
+$25.3M
5
UNH icon
UnitedHealth
UNH
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 77.22%
2 Financials 2.61%
3 Communication Services 2.08%
4 Consumer Staples 1.23%
5 Industrials 0.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$90.6M 9.27%
10,718,420
+437,800
+4% +$3.1M
MDVN
2
DELISTED
MEDIVATION, INC.
MDVN
$82.1M 8.41%
1,786,599
+187,206
+12% +$6.79M
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
$59.5M 6.09%
3,099,336
+1,303,400
+73% +$27.6M
PEN icon
4
Penumbra
PEN
$12.5B
$58.3M 5.97%
1,267,967
-269,603
-18% -$12.6M
ARRY
5
DELISTED
Array Biopharma Inc
ARRY
$56.5M 5.78%
19,150,650
+1,300,000
+7% +$3.9M
IRWD icon
6
Ironwood Pharmaceuticals
IRWD
$632M
$47.3M 4.84%
5,158,309
+774,724
+18% +$6.39M
ATRA icon
7
Atara Biotherapeutics
ATRA
$75M
$43.3M 4.43%
91,031
+29,633
+48% +$13.3M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.5B
$39.4M 4.04%
+478,287
New +$38.9M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$34M 3.48%
970,121
-402,371
-29% -$13.5M
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$33.8M 3.46%
1,053,018
+94,644
+10% +$3.33M
AGN
11
DELISTED
Allergan plc
AGN
$30.7M 3.14%
114,448
+45,690
+66% +$13.1M
ITCI
12
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$29.4M 3%
1,056,059
-167,658
-14% -$5.59M
CNC icon
13
Centene
CNC
$32.8B
$29M 2.97%
941,098
+125,098
+15% +$3.73M
NSTG
14
DELISTED
NanoString Technologies, Inc.
NSTG
$28.4M 2.9%
1,863,035
+505,343
+37% +$7.14M
BSX icon
15
Boston Scientific
BSX
$64.5B
$25.1M 2.57%
1,332,520
-918,500
-41% -$16.1M
BKD icon
16
Brookdale Senior Living
BKD
$3.58B
$22.7M 2.32%
+1,428,931
New +$21.8M
AET
17
DELISTED
Aetna Inc
AET
$21.5M 2.2%
+191,625
New +$20.5M
MOH icon
18
Molina Healthcare
MOH
$11.8B
$21.2M 2.17%
+329,013
New +$19.5M
ELGX
19
DELISTED
Endologix Inc
ELGX
$20.6M 2.11%
246,885
+146,167
+145% +$12M
MODN
20
DELISTED
MODEL N, INC.
MODN
$20.3M 2.08%
1,885,359
+17,200
+0.9% +$180K
PTLA
21
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$18.1M 1.86%
889,607
-68,548
-7% -$2.17M
WVE icon
22
Wave Life Sciences
WVE
$1.12B
$17M 1.74%
1,238,273
+24,646
+2% +$345K
NDRM
23
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$16.7M 1.71%
1,180,887
-408,374
-26% -$5.52M
INCY icon
24
Incyte
INCY
$23.6B
$15.7M 1.61%
216,594
-141,318
-39% -$10.5M
WOOF
25
DELISTED
VCA Inc.
WOOF
$12M 1.23%
+207,800
New +$10.8M
1
2 3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q1 2016 Portfolio in Review

As of Q1 2016, Redmile Group held 68 positions worth $977M, down 27% from $1.34B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Redmile Group withdrew a net $135M in Q1 2016, closing 21 positions and reducing 16 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $61.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 77% a quarter earlier, followed by Financials and Communication Services.

Against the trend, Redmile Group opened a new position in BioMarin Pharmaceuticals worth $39.4M.

  • Redmile Group's largest Q1 2016 buy was BioMarin Pharmaceuticals: 478,287 shares worth $39.4M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q1 2016, an estimated $27.6M increase.
  • Redmile Group's biggest Q1 2016 reduction was NEVRO CORP., cutting an estimated $16.8M.
  • Redmile Group fully exited Teva Pharmaceuticals in Q1 2016, selling an estimated $61.6M.
  • Redmile Group's ten largest holdings make up 56% of its $977M portfolio in Q1 2016.
  • Redmile Group opened 11 new positions and closed 21 in Q1 2016.
  • Redmile Group's portfolio value fell 27% quarter-over-quarter to $977M.

Based on Redmile Group's 13F filing for Q1 2016, filed 16 May 2016.